Buck Institute press release on TPE biological-age trial
news article · 2025
LINK
SUMMARY
Buck Institute's public communication of the *Aging Cell* trial findings, released in conjunction with the May 2025 publication. The press release reproduces the headline 2.61-year biological-age-reduction figure for biweekly TPE+IVIG and the 1.32-year figure for monthly TPE alone, and frames the results cautiously as early data from the first interventional multi-omics study of therapeutic plasma exchange rather than as a settled result. Together with Circulate Health's own marketing materials, the press release is the principal public-facing communication of the trial findings beyond the *Aging Cell* primary publication. Subsequent press coverage (including New York Times features and lifestyle-medicine reporting) traced its framing through this institutional release.
NOTES
The Buck Institute press release is the institutional communication of the trial findings to non-specialist audiences. It establishes the framing under which the trial entered the broader longevity-medicine and elite-health-services market. The release is the appropriate reference for any discussion of the public reception and commercial deployment of the trial findings; the underlying scientific claims should be checked against the Aging Cell primary publication rather than the press release.